PL2799070T3 - Środek wzmacniający działanie środków przeciwnowotworowych - Google Patents

Środek wzmacniający działanie środków przeciwnowotworowych

Info

Publication number
PL2799070T3
PL2799070T3 PL12863476T PL12863476T PL2799070T3 PL 2799070 T3 PL2799070 T3 PL 2799070T3 PL 12863476 T PL12863476 T PL 12863476T PL 12863476 T PL12863476 T PL 12863476T PL 2799070 T3 PL2799070 T3 PL 2799070T3
Authority
PL
Poland
Prior art keywords
antitumor agents
effect potentiator
potentiator
effect
antitumor
Prior art date
Application number
PL12863476T
Other languages
English (en)
Inventor
Hidenori Fujita
Masanori Kato
Original Assignee
Taiho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co., Ltd. filed Critical Taiho Pharmaceutical Co., Ltd.
Publication of PL2799070T3 publication Critical patent/PL2799070T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL12863476T 2011-12-28 2012-12-27 Środek wzmacniający działanie środków przeciwnowotworowych PL2799070T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011290125 2011-12-28
PCT/JP2012/083794 WO2013100014A1 (ja) 2011-12-28 2012-12-27 抗腫瘍剤の効果増強剤
EP12863476.3A EP2799070B1 (en) 2011-12-28 2012-12-27 Effect potentiator for antitumor agents

Publications (1)

Publication Number Publication Date
PL2799070T3 true PL2799070T3 (pl) 2019-07-31

Family

ID=48697493

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12863476T PL2799070T3 (pl) 2011-12-28 2012-12-27 Środek wzmacniający działanie środków przeciwnowotworowych

Country Status (13)

Country Link
US (1) US20140378409A1 (pl)
EP (1) EP2799070B1 (pl)
JP (1) JP5852678B2 (pl)
KR (1) KR101668931B1 (pl)
AU (2) AU2012361581B2 (pl)
DK (1) DK2799070T3 (pl)
ES (1) ES2717898T3 (pl)
HU (1) HUE043991T2 (pl)
PL (1) PL2799070T3 (pl)
PT (1) PT2799070T (pl)
RU (1) RU2589713C2 (pl)
TW (1) TWI594986B (pl)
WO (1) WO2013100014A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105683195B (zh) 2013-08-22 2017-11-10 大鹏药品工业株式会社 喹啉取代的化合物
US9149471B2 (en) 2013-09-30 2015-10-06 National University Corporation Tokyo University Of Agriculture And Technology Therapeutic agent for osteoporosis
WO2016175305A1 (ja) * 2015-04-30 2016-11-03 大鵬薬品工業株式会社 アシルチオウレア化合物のメシル酸塩及びその結晶並びにそれらの製造方法
US10449189B2 (en) 2015-06-25 2019-10-22 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for fibrosis
EP3508205B1 (en) * 2016-08-31 2022-05-18 FUJIFILM Corporation Anti-tumor agent, anti-tumor effect enhancer, and anti-tumor kit
JOP20190073A1 (ar) 2016-10-31 2019-04-07 Taiho Pharmaceutical Co Ltd مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20
DK3583943T3 (da) 2017-02-15 2024-10-14 Taiho Pharmaceutical Co Ltd Farmaceutisk sammensætning
MX2020002296A (es) 2017-09-01 2020-09-10 Taiho Pharmaceutical Co Ltd Inhibidor selectivo de egfr mutado en el exon 18 y/o el exon 21.
KR102584306B1 (ko) 2017-09-08 2023-10-04 다이호야쿠힌고교 가부시키가이샤 항종양제 및 항종양 효과 증강제
CA3089728C (en) 2018-01-29 2023-01-10 Fujifilm Corporation Antitumor agent for biliary tract cancer and method for treating biliary tract cancer
AU2019233338B2 (en) 2018-03-13 2022-08-18 Fujifilm Corporation Antitumor agent, antitumor effect potentiator and antitumor kit
MA53667A (fr) 2018-09-18 2021-07-28 Taiho Pharmaceutical Co Ltd Polythérapie associant un composé d'acylthiourée et de l'abiratérone
TWI872203B (zh) * 2020-02-14 2025-02-11 日商大鵬藥品工業股份有限公司 醯基硫脲化合物的製造方法
CN117820332B (zh) * 2024-03-04 2024-05-14 烟台大学 苯并噻吩-硫脲类化合物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60137273D1 (de) * 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
AU2006231646A1 (en) * 2005-04-06 2006-10-12 Exelixis, Inc. C-Met modulators and methods of use
WO2009096377A1 (ja) 2008-01-29 2009-08-06 Eisai R & D Management Co., Ltd. 血管阻害物質とタキサンとの併用
JP2011513427A (ja) * 2008-03-06 2011-04-28 ジェネンテック, インコーポレイテッド c−met及びEGFRアンタゴニストの併用療法
MX2010011097A (es) * 2008-04-10 2010-11-01 Taiho Pharmaceutical Co Ltd Compuesto de aciltiourea o sal del mismo, y uso del mismo.
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
US20110104161A1 (en) * 2008-05-14 2011-05-05 Burgess Teresa L Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
CN102481299B (zh) * 2009-02-12 2015-02-25 艾科尔公司 包括与第二抗增殖性试剂结合的(-)-反式-3-(5,6-二氢-4H-吡咯[3,2,1-ij]喹啉-1-基)-4-(1H-吲哚-3-基)吡咯烷-2,5-二酮的组合物

Also Published As

Publication number Publication date
EP2799070A4 (en) 2015-05-27
RU2589713C2 (ru) 2016-07-10
DK2799070T3 (en) 2019-04-23
RU2014131058A (ru) 2016-02-20
US20140378409A1 (en) 2014-12-25
JPWO2013100014A1 (ja) 2015-05-11
AU2012361581B2 (en) 2016-06-30
TWI594986B (zh) 2017-08-11
AU2012361581A1 (en) 2014-07-24
TW201331182A (zh) 2013-08-01
JP5852678B2 (ja) 2016-02-03
WO2013100014A1 (ja) 2013-07-04
KR20140096375A (ko) 2014-08-05
AU2016204054A1 (en) 2016-07-07
KR101668931B1 (ko) 2016-10-24
HUE043991T2 (hu) 2019-09-30
PT2799070T (pt) 2019-04-03
EP2799070A1 (en) 2014-11-05
ES2717898T3 (es) 2019-06-26
EP2799070B1 (en) 2019-02-13

Similar Documents

Publication Publication Date Title
DK2691417T4 (en) Antistof fc-varianter
PL2799070T3 (pl) Środek wzmacniający działanie środków przeciwnowotworowych
SG10201601802YA (en) Dispiropyrrolidine derivatives
GB201109414D0 (en) Diathermy -ionisation technique
EP2787386A4 (en) MASK
IL247640A0 (en) History of heteroaryl piperidine
ZA201403050B (en) R(+)-n-methyl-propargyl-aminoindan
AP2014007621A0 (en) 2-Thiopyrimidinones
PL2543408T3 (pl) Maska do wspomagania oddychania
PT2868660T (pt) Composto de imidazo-oxazina potenciador de um efeito anti-tumor
EP2691581A4 (en) joint assembly
ZA201403043B (en) R(+)-n-formyl-propargyl-aminoindan
SI2766342T1 (sl) Derivati fenil-gvanidina
ZA201308049B (en) 3-ureidoisoquinolin-8-yl derivatives
IL216134A0 (en) Polygraph
AU5171P (en) Sunparamiho Mandevilla xamabilis
AU5031P (en) BESYS Beschorneria yuccoides
AU5026P (en) Goldstrike Agapanthus inapertus
GB201114668D0 (en) Masking means
GB201114015D0 (en) Lock-through slit
GB201100370D0 (en) Concept seven
GB201117537D0 (en) Citizen-activated-police-response citizen activated-emergency-response
AU337485S (en) Cabin
ZA201209319B (en) Cyclopropyl-indole derivatives
GB201114533D0 (en) Concept 36A